Randy Randy, Yosua Khandar, Guntara Aswin, Hardiansyah Nicko P
Emergency Department, Mayapada Hospital Kuningan, Jakarta, Indonesia
Emergency Department, Betang Pambelum Hospital, Palangka Raya, Indonesia.
Int J Spine Surg. 2025 May 12;19(2):156-167. doi: 10.14444/86717.
Low back pain (LBP) is 1 of the most common problems that present in 80% of people. LBP can be caused by some pathologies, with discogenic pain being 1 source. Pain from LBP can become chronic and also cause disability. Treatment options for LBP varied from conservative to operative, and a novel treatment nowadays is using stem cells therapy to treat with pain from LBP.
Database searches from Pubmed and ScienceDirect from inception to 13 September 2023. A total of 283 discogenic LBP cases from 8 articles. This study measured clinical outcomes using a visual analog scale (VAS) and Oswestry Disability Index (ODI) obtained from each study.
Functional outcomes in patients treated with stem cell therapy showed significant improvement ODI and VAS ( < 0.00001). Improvement also showed in Pfirrmann grade before and after treatment with stem cells ( = 0.005). Subgroup analyses using bone marrow aspirate concentrate also showed significant differences in both ODI and VAS ( < 0.00001).
Stem cells therapy could be beneficial as an option of treatment for discogenic LBP in improving pain and activity of daily living.
Intradiscal stem cell therapy is a promising alternative for managing discogenic low back pain, offering improvements in pain and function.
腰痛（LBP）是最常见的问题之一，80%的人都曾出现过。LBP可能由某些病理状况引起，椎间盘源性疼痛是其中一个原因。LBP引发的疼痛可能会变为慢性，还会导致残疾。LBP的治疗选择从保守治疗到手术治疗不等，如今一种新的治疗方法是使用干细胞疗法来治疗LBP引起的疼痛。
检索了从创刊至2023年9月13日的Pubmed和ScienceDirect数据库。共纳入8篇文章中的283例椎间盘源性LBP病例。本研究使用从每项研究中获取的视觉模拟量表（VAS）和奥斯维斯特残疾指数（ODI）来衡量临床结果。
接受干细胞治疗的患者的功能结果显示，ODI和VAS有显著改善（<0.00001）。干细胞治疗前后的Pfirrmann分级也有改善（=0.005）。使用骨髓抽吸浓缩物的亚组分析在ODI和VAS方面也显示出显著差异（<0.00001）。
干细胞疗法作为椎间盘源性LBP的一种治疗选择，在改善疼痛和日常生活活动方面可能是有益的。
椎间盘内干细胞疗法是治疗椎间盘源性腰痛的一种有前景的替代方法，可以改善疼痛和功能。
